Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

1041P - Explore the efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients of different gender


17 Sep 2020


E-Poster Display


Shu-yue Zheng


Annals of Oncology (2020) 31 (suppl_4): S645-S671. 10.1016/annonc/annonc279


S. Zheng1, H. Cui2

Author affiliations

  • 1 Graduate School, Beijing University of Chinese Medicine, 100029 - Beijing/CN
  • 2 Department Of Integrative Oncology, China-Japan Friendship Hospital, 100029 - Beijing/CN


Abstract 1041P


Gender associated differences in immune response are common. Latest clinical trials have proved the better overall survival (OS) for the use of immune checkpoint inhibitors (ICIs) verse chemotherapy in non-small cell lung cancer (NSCLC) patients. However, we still have no clear ideas of the efficacy of them in different gender. Therefore, we conducted a meta-analysis to compare the efficacy of ICIs for NSCLC patients of different gender groups and summarized overall treatment-related adverse events.


PubMed, EMBASE, Web of Science and the Cochrane Library were searched for all clinical trials in NSCLC until 28th of July 2019. Eligible studies included randomized controlled trials (RCTs) comparing ICIs with chemotherapy in NSCLC patients. The hazard ratio (HRs) and 95% confidence intervals (CIs) of OS, progression-free survival (PFS) or adverse events (AEs) were used.


A total of 5199 patients from 8 RCTs were included. ICIs significantly prolonged the OS (HR, 0.75; 95% CI, 0.67–0.84) and PFS (HR, 0.62; 95% CI, 0.47–0.83) versus chemotherapy in male NSCLC patients. Also, they prolonged the OS (HR, 0.62; 95% CI, 0.45–0.87) in female NSCLC patients. However, there was no statistical significance of PFS (HR, 0.64; 95% CI, 0.39–1.04) among female NSCLC patients. It also showed that the single use of ICIs had fewer all-grade AEs compared with the combination of ICIs and chemotherapy.


NSCLC patients could achieve better OS from ICIs than chemotherapy treatment regardless of their gender. But there was no significant difference in the PFS of female NSCLC patients. Male patients might be likely to get better results in the treatment of ICIs which needs to be further investigated.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Capital’s Funds for Health Improvement and Research (No.2018-2-4065), National Natural Science Foundation of China (No. 81873396) and China-Japan Friendship Hospital.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.